The biotechnology innovation machine: A source of intelligent biopharmaceuticals for the pharma industry - Mapping biotechnology's success

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 5, 2014, Pages 528-532

  Evens, R P ^a,b,c   Kaitin, K I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c M A P S 4 Biotec   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTISENSE OLIGONUCLEOTIDE; APTAMER; INSULIN; MACROGOL; MONOCLONAL ANTIBODY; POLYMER; PROTEIN; RECOMBINANT DNA; RECOMBINANT VACCINE; RNA; SYNTHETIC PEPTIDE;

ARTICLE; BIOTECHNOLOGY; CELL THERAPY; CLINICAL RESEARCH; DISEASE CONTROL; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; FINANCIAL MANAGEMENT; HUMAN; INVESTMENT; PATENT; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REIMBURSEMENT; RNA INTERFERENCE; TISSUE ENGINEERING;

BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; DELIVERY OF HEALTH CARE; DRUG INDUSTRY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PATENTS AS TOPIC; PATIENT CARE; RESEARCH;

EID: 84899459590     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.14     Document Type: Article

References (20)

1. Mathieu, M. (ed.). Chapter 1. What is a biologic? In Biologics Development: A Regulatory Overview 3rd edn, 1-16 (Parexel International Corporation, Waltham, MA, 2004).
2. Evens, R.P. Biotechnology and biological preparations. In Encyclopedia of Pharmaceutical Science and Technology 4th edn. Vol. 1. (ed. Swarbrick, J) 239-266 (Taylor & Francis Group, Boca Raton, Florida, 2013).
3. Anonymous. World Preview 2013, Outlook to 2018. Return to Growth (EvaluatePharma, London, 2013).
4. Aitken, M. The global use of medicines: outlook through 2017. (IMS Institute for Healthcare Informatics, Parsippany, NJ, 2012).
5. Anonymous. Top 20 global corporations 2012. (IMS Health, Parsippany, NJ, 2012).
6. Truelove, C. 27th Annual Report. Top 50 Pharma Companies. MedAdNews. 32, 6-20 (2012).
7. Humphreys, A. 23rd Annual Report. Top 100 Medicine Highlights. MedAdNews. 32, 12-17 (2013).
8. Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917-924 (2010).
9. Holmer, A.F. 2000 Survey. New medicine in development. Biotechnology. (Pharmaceutical Research and Manufacturers of America, Washington, DC, 2000).
10. Tauzin, B. 2008 Report. Medicines in development. Biotechnology. (Pharmaceutical Research and Manufacturers of America, Washington, DC, 2008).
11. Anonymous. 2013 Report. Medicines in development. Biologics. (Pharmaceutical Research and Manufacturers of America, Washington, DC, 2013).
12. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010).
13. Philippidis, A. Large molecules continue to gain favor. Genetic Engineering & Biotechnology News 32, 10-11 (2012).
14. Steever, S.B. & Swanson, G.S. Leading biotechnology mergers and acquisitions for the 10-year period ended December 31, 2009 revealed by dealsearchonbline.com. 〈http://www.levinassociates.com/pr2010/ pr1003biotech〉 (2010).
15. Giovannetti, G.T. & Jaggi, G. (eds). Beyond borders. Global biotechnology report. (Ernst & young, Boston, MA, 2009).
16. Huggett, B., Hodgson, J. & Lähteenmäki, R. Public biotech 2009-the numbers. Nat. Biotechnol. 28, 793-799 (2010).
17. Giovannetti, G.T. & Jaggi, G. (eds). Beyond borders. Biotechnology industry report 2013. (Ernst & young, San Francisco, CA, 2013).
18. Giovannetti, G.T. & Morrison, S.W. (eds). Convergence. The biotechnology industry report. Millenium edition. (Ernst & young, San Francisco, CA, 2000).
19. Giovannetti, G.T. & Jaggi, G. (eds). Beyond borders. Global biotechnology industry report 2010. (Ernst & young, San Francisco, CA, 2010).
20. Aggarwal, S. What's fueling the biotech engine-2009-2010. Nat. Biotechnol. 28, 1165-1171 (2010).